MC
TRDA icon

Merck & Co’s Entrada Therapeutics TRDA Stock Holding History

Merck & Co’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22M Hold
1,739,768
– – 6.28% 4
2025
Q4 		$17.9M Hold
1,739,768
– – 6.47% 4
2025
Q3 		$10.1M Hold
1,739,768
– – 4.43% 5
2025
Q2 		$11.7M Hold
1,739,768
– – 5.42% 4
2025
Q1 		$15.7M Hold
1,739,768
– – 9.57% 4
2024
Q4 		$30.1M Buy
+1,739,768
New +$31.5M 11.66% 4

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Merck & Co's TRDA Position: Q1 2026 in Review

Merck & Co held its Entrada Therapeutics (TRDA) position steady in Q1 2026 at 1,739,768 shares worth $22M. The position accounts for 6.28% of the portfolio, ranked #4.

Merck & Co first reported a position in TRDA in Q4 2024 and has held it in 6 quarters since. The position peaked at $30.1M in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Merck & Co held 1,739,768 shares of Entrada Therapeutics worth $22M as of Q1 2026.
  • Merck & Co left its Entrada Therapeutics share count unchanged in Q1 2026.
  • Entrada Therapeutics made up 6.28% of Merck & Co's portfolio in Q1 2026, its #4 holding.
  • Merck & Co first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Merck & Co's Entrada Therapeutics position peaked at $30.1M in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.